search
Back to results

Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition (REDMOTHIV)

Primary Purpose

HIV-1-infection, Malnutrition, Child

Status
Recruiting
Phase
Phase 2
Locations
Uganda
Study Type
Interventional
Intervention
Ceftriaxone Sodium
Ampicillin
Gentamicin
Sponsored by
Makerere University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV-1-infection

Eligibility Criteria

1 Month - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. HIV-infected children aged 1 to 59 months admitted at Mwanamugimu Nutrition Unit with severe acute malnutrition
  2. HIV exposed but uninfected children aged 1 to 59 months admitted at Mwanamugimu Nutrition Unit with severe acute malnutrition
  3. For prevalence of HIV-infection sub-study, children presenting with severe acute malnutrition on admission at Mwanamugimu Nutrition Unit.
  4. For PK sub-study, the child should have been on antiretroviral therapy for at least 2weeks and should have been in hospital for at least 2weeks.

Exclusion Criteria:

  • For PK sub-study; a child with documented poor adherence to antiretroviral therapy.
  • For PK sub-study; a child known to have vomited the drug on the sampling day.

Sites / Locations

  • Makerere University College of Health SciencesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Ceftriaxone

Ampicillin and Gentamicin

Arm Description

Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily

Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly Gentamicin will be administered intravenously at a dose 5mg/kg once daily

Outcomes

Primary Outcome Measures

In hospital mortality
Cumulative incidence

Secondary Outcome Measures

Length of hospitalization
Number of days
Weight-for-height z-score
Change from baseline
Weight-for-age z-score
Change from baseline
Height-for-age z-score
Change from baseline
Pattern and antimicrobial sensitivity of pathogens
Frequency
HIV infection
Prevalence
Area under the curve (AUC 0- 12h)
Geometric means
Maximum concentration (Cmax)
Geometric means
Concentration at 12hours post dose (C12h)
Geometric means

Full Information

First Posted
August 6, 2021
Last Updated
September 24, 2021
Sponsor
Makerere University
search

1. Study Identification

Unique Protocol Identification Number
NCT05051163
Brief Title
Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition
Acronym
REDMOTHIV
Official Title
A Randomized Trial to Investigate Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition in Mulago Hospital, Kampala, Uganda
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Recruiting
Study Start Date
June 14, 2021 (Actual)
Primary Completion Date
June 14, 2024 (Anticipated)
Study Completion Date
June 14, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Makerere University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study to investigate whether empiric use of an antibiotic with greater antimicrobial sensitivity (ceftriaxone) than standard-of-care (ampicillin plus gentamicin) will reduce mortality among HIV-infected/HEU children admitted to Mwanamugimu Nutrition Unit, Mulago Hospital, Kampala, Uganda.
Detailed Description
Background HIV-infected and HIV-exposed-uninfected children (HEU) are at increased risk of developing malnutrition. Severely malnourished children have high mortality rates, but mortality is higher in those that are HIV-infected. Preliminary audits at the Mwanamugimu Nutrition Unit, Mulago Hospital, in 2014 showed that 43% of the severely malnourished children that died were HIV-infected/HEU, despite only 30% of admissions being HIV-infected/HEU, with deaths due to infections in 90% of cases. Objectives This study aims to investigate whether empiric use of an antibiotic with greater antimicrobial sensitivity (ceftriaxone) than standard-of-care (ampicillin plus gentamicin) will reduce mortality among HIV-infected/HEU children admitted to Mwanamugimu Nutrition Unit. Secondary objectives include: comparing length of hospitalization, weight-for-height, weight-for-age and height-for-age z-scores between ceftriaxone versus standard of care (ampicillin and gentamicin) treatment arms; ascertaining the pattern/antimicrobial sensitivity of pathogens among participants; determining the prevalence and factors associated with HIV-infection among severely malnourished children; and evaluating the pharmacokinetics (PK) of lopinavir/ritonavir (LPV/r) among severely malnourished HIV-infected children. Methods This will be an open label randomized controlled trial involving 300 children; 76 HIV-infected (current mortality - 33%) and 224 HEU (current mortality - 26%). The participants will be randomized to receive 1week of ceftriaxone (n= 150) or standard-of-care (ampicillin/gentamicin) (n=150), in addition to other routine care; the ratio of HIV-infected to HEU (1:3) in this sample is reflective of the current proportions of the HIV-infected and HEU children admitted at Mwanamugimu Nutrition Unit. The trial's primary outcome will be in hospital mortality. 300 randomised children provides >80% power to detect reductions in mortality from the expected 28% to 14%, allowing for 10% noncompliance/lost-to-follow-up in each group. Secondary outcomes will be: length of hospitalization; weight-for-height, weight-for-age and height-for-age z-scores; and pattern/antimicrobial sensitivity of pathogens. In addition, 280 severely malnourished children of unknown serostatus will be tested for HIV at admission to determine the prevalence and factors associated with HIV-infection. 280 children provide 80% power to determine the prevalence of HIV-infection. Furthermore, all the HIV-infected children on LPV/r will each provide sparse pharmacokinetic (PK) samples to evaluate the PK of LPV/r among malnourished children. In this PK sub-study, geometric means of steady-state LPV PK parameters [Area Under the Curve (AUC) 0-12h, maximum concentration (Cmax) and concentration at 12 hours after dose (C12h)] will be determined. The PK parameters (AUC 0-12h, Cmax, C12) will then be put in pharmacokinetic-pharmacodynamic (PK-PD) models to determine optimal doses for the study population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV-1-infection, Malnutrition, Child

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Open label parallel group randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ceftriaxone
Arm Type
Experimental
Arm Description
Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily
Arm Title
Ampicillin and Gentamicin
Arm Type
Active Comparator
Arm Description
Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly Gentamicin will be administered intravenously at a dose 5mg/kg once daily
Intervention Type
Drug
Intervention Name(s)
Ceftriaxone Sodium
Other Intervention Name(s)
ZEFONE-1000
Intervention Description
7 days of once daily dosing
Intervention Type
Drug
Intervention Name(s)
Ampicillin
Other Intervention Name(s)
AMPIMAX-500
Intervention Description
7 days of 6 hourly dosing
Intervention Type
Drug
Intervention Name(s)
Gentamicin
Other Intervention Name(s)
GENTAMICIN INJECTION
Intervention Description
7 days of once daily dosing
Primary Outcome Measure Information:
Title
In hospital mortality
Description
Cumulative incidence
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Length of hospitalization
Description
Number of days
Time Frame
90 days
Title
Weight-for-height z-score
Description
Change from baseline
Time Frame
90 days
Title
Weight-for-age z-score
Description
Change from baseline
Time Frame
90 days
Title
Height-for-age z-score
Description
Change from baseline
Time Frame
90 days
Title
Pattern and antimicrobial sensitivity of pathogens
Description
Frequency
Time Frame
7 days
Title
HIV infection
Description
Prevalence
Time Frame
Baseline
Title
Area under the curve (AUC 0- 12h)
Description
Geometric means
Time Frame
12hours
Title
Maximum concentration (Cmax)
Description
Geometric means
Time Frame
12hours
Title
Concentration at 12hours post dose (C12h)
Description
Geometric means
Time Frame
12hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HIV-infected children aged 1 to 59 months admitted at Mwanamugimu Nutrition Unit with severe acute malnutrition HIV exposed but uninfected children aged 1 to 59 months admitted at Mwanamugimu Nutrition Unit with severe acute malnutrition For prevalence of HIV-infection sub-study, children presenting with severe acute malnutrition on admission at Mwanamugimu Nutrition Unit. For PK sub-study, the child should have been on antiretroviral therapy for at least 2weeks and should have been in hospital for at least 2weeks. Exclusion Criteria: For PK sub-study; a child with documented poor adherence to antiretroviral therapy. For PK sub-study; a child known to have vomited the drug on the sampling day.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Victor Musiime, PhD
Phone
+256772401749
Email
musiimev@yahoo.co.uk
Facility Information:
Facility Name
Makerere University College of Health Sciences
City
Kampala
State/Province
Central
ZIP/Postal Code
7072
Country
Uganda
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Victor Musiime, PhD
Phone
0772401749
Email
musiimev@yahoo.co.uk
First Name & Middle Initial & Last Name & Degree
Victor Musiime, PhD
First Name & Middle Initial & Last Name & Degree
Philippa Musoke, PhD
First Name & Middle Initial & Last Name & Degree
Jackson Mukonzo, PhD
First Name & Middle Initial & Last Name & Degree
Willy Ssengooba, PhD
First Name & Middle Initial & Last Name & Degree
Esther Babirekere, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
When results are required as part of a meta-analysis or as secondary data.
IPD Sharing Time Frame
1 year after end of data collection
IPD Sharing Access Criteria
On request to Principal Investigator
Citations:
PubMed Identifier
35813373
Citation
Musiime V, Kiggwe A, Beinomugisha J, Kakooza L, Thembo-Mwesige J, Nkinzi S, Naguti E, Atuhaire L, Segawa I, Ssengooba W, Mukonzo JK, Babirekere-Iriso E, Musoke P. Strategies to Reduce Mortality Among Children Living With HIV and Children Exposed to HIV but Are Uninfected, Admitted With Severe Acute Malnutrition at Mulago Hospital, Uganda (REDMOTHIV): A Mixed Methods Study. Front Pediatr. 2022 Jun 24;10:880355. doi: 10.3389/fped.2022.880355. eCollection 2022.
Results Reference
derived

Learn more about this trial

Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition

We'll reach out to this number within 24 hrs